September 19th, 2023 | Meeting Studio 212 – 12:30pm 1:30pm EST
In a context of sourcing challenges and rising costs, choosing the best animal model, and optimizing data collection is a major concern for safety pharmacology studies.
This scientific panel will gather scientists that will present the benefits and insights obtained from rodent and non-rodent species, in recent experiments:
Swine, the Other Tox Species (or Beyond Medical Device Testing). Dr. Donald Hodges – CBSET
Use of the Rat in Cardiovascular Screening Assays for Preclinical Compounds. Dr. Michael J. Stonerook – AmplifyBio
Using non-CV functional measurements to interpret complex phenomena in efficacy and safety research. Dr. Dany Salvail – IPS Therapeutique
Space is limited. Register to save your seat!
Dr. Michael Stonerook is the lead Safety Pharmacologist and Chief Surgeon for AmplifyBio, a contract research organization focused on discovery, manufacturing, and preclinical drug development with cell and gene therapy products and new chemical entities.
He also holds an appointment as an Adjunct Assistant Professor in the College of Veterinary Medicine with teaching responsibilities in Physiology, Pharmacology, and Toxicology. Dr. Stonerook was an attendee of the General and Safety Pharmacology Group Meetings (1997-1999) that gave rise to the Safety Pharmacology Society, of which he was an inaugural member.
Dr. Stonerook has participated in many roles during his career including Attending Veterinarian, surgical veterinarian, study director for pharmaceutical safety pharmacology studies and general toxicology studies (GLP and non-GLP), production of IND packages, and manager/director of research groups.
Dr. Stonerook’s research experience includes the direction and evaluation of cardiovascular safety studies, respiratory safety studies, inhalation delivery studies, and intravenous infusion studies (ambulatory and non-ambulatory in multiple species). Additionally, he has had roles in the development and testing of equipment and animal models currently in use in safety pharmacology studies throughout the industry.
Dan Salvail completed his undergraduate training in Biochemistry at Bishop’s University, in Canada, before being granted a Ph.D in Thoracic Physiology & Biophysics at the University of Sherbrooke.
While pursuing post-graduate training in cardiology, he co-founded IPS Therapeutique Inc., a CRO specialized in preclinical cardiovascular efficacy and safety assessment, in which he still holds a management role. As Director of Pharmacology and then Vice-President, he has assembled preclinical drug development, and safety testing strategies for dozens of compounds, and overseen testing for 3 000 + drug candidates over the last 24 years.
The experience gained with dozens of classes of compounds and the central role played in the development of highly successful drugs led to international recognition, presentations given in North America, Europe, Asia, and subsequent requests to act as a consultant in preclinical cardiology.
To complement the service offer from IPS Therapeutique Inc., he co-founded ToxiPharm Laboratories Inc., a hybrid CRO-expert consultation group which relied on academic and industry experts to develop customized preclinical solutions for unique applications, models, and molecules. His involvement with ToxiPharm provided a framework for more consultant work, focusing on the efficacy and safety assessment of promising drug candidates targeting non-cardiac diseases.
When you visit any web site, it may store or retrieve information on your browser, mostly in the form of cookies. Control your personal Cookie Services here.